Sphingosine-1-phosphate and Pneumonia

Launched by TAIPEI MEDICAL UNIVERSITY WANFANG HOSPITAL · Jul 2, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a substance called Sphingosine-1-phosphate (S1P) and its role in pneumonia, particularly a type called community-acquired pneumonia (CAP). Researchers believe that S1P could help in understanding how pneumonia develops and may even serve as a useful marker for diagnosing the condition. They also want to explore whether S1P can indicate if treatment with corticosteroids, a type of medication used to reduce inflammation, might be helpful for patients with pneumonia.

To participate in this trial, individuals need to be at least 18 years old and show symptoms of pneumonia that are considered severe. However, there are some exclusions, such as those with severe immune system issues, certain cancers, or those currently on antibiotics or corticosteroids. Participants will be part of a study that aims to improve the understanding of pneumonia and potentially enhance treatment options. If you or a loved one is interested and meets the criteria, it could be a valuable opportunity to contribute to important medical research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical symptoms suggestive community-acquired pneumonia and pneumonia severe index (PSI) \> 90, Age 18 years or older and Written informed consent obtained
• Exclusion Criteria:
• • Presence of severe immunosuppression (HIV infection, use of immunosuppressants), malignancy, pregnancy or breastfeeding, patient with uncontrol diabetes, current use of antibiotics or corticosteroids, any likely infection other than CAP, or pneumonia that developed within 3 days after hospital discharge